| Name | Title | Contact Details |
|---|
Vilex is an innovative manufacturer of orthopaedic internal and external fixation devices, plates, and small joint implants.
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.
Tiber Laboratories is a Suwanee, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardiocore Lab, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so difficult. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients. At Agios, we`re always looking for the sweet spot between exhilaration and anxiety – while being respectful, kind and connected with each other so we can flourish. At our core, we`re a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients. We`re a science-driven, global organization that`s built a discovery platform on our expertise across three major focus areas: cancer metabolism, rare genetic diseases and metabolic immuno-oncology. And we care. A lot. Patients are counting on us, and we`re driven by a sense of urgency to help. We challenge ourselves to think big and welcome different perspectives and backgrounds. And we deliver. We have two approved oncology precision medicines and multiple first-in-class investigational therapies in development. So far. Through it all, we are propelled by our connections. We believe in our people to be…just who they are. We believe in our work and in each other – in enjoying this journey together so that we can achieve the Other Side of Possible.